PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents

Small cell lung cancer (SCLC) is a highly aggressive form of cancer, commonly treated with DNA-damaging therapies such as chemotherapy and radiotherapy. Unfortunately, relapse occurs early and frequently, suggesting that epigenetic mechanisms may play a role in this aggressive behavior. Targeting th...

Full description

Saved in:
Bibliographic Details
Main Authors: Mansi K. Aparnathi, Sami Ul Haq, Jonathan St-Germain, Kevin C.J. Nixon, Joseph Walton, Lifang Song, Safa Majeed, Parasvi S. Patel, Ratheesh Subramaniam, Vivek Philip, Richard Marcellus, Dalia Barsyte-Lovejoy, Rima Al-Awar, Razqallah Hakem, Cheryl H. Arrowsmith, Laurie Ailles, Brian Raught, Benjamin H. Lok
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Drug synergy
Small cell lung cancer, Poly(ADP-Ribose) polymerase
PARP inhibitor
Chemotherapy
Radiation therapy
Epigenetics
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000557
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1476558625000557

Similar Items